Pereira Patrícia, Barreira Maria, Cruz Carla, Tomás Joana, Luís Ângelo, Pedro Augusto Q, Queiroz João A, Sousa Fani
CICS-UBI-Health Sciences Research Centre, University of Beira Interior, Avenida Infante D. Henrique, 6200-506 Covilhã, Portugal.
Department of Chemical Engineering, Centre for Mechanical Engineering, Materials and Processes, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal.
Pharmaceuticals (Basel). 2020 Oct 15;13(10):314. doi: 10.3390/ph13100314.
The efficacy of brain therapeutics is largely hampered by the presence of the blood-brain barrier (BBB), mainly due to the failure of most (bio) pharmaceuticals to cross it. Accordingly, this study aims to develop nanocarriers for targeted delivery of recombinant precursor microRNA (pre-miR-29b), foreseeing a decrease in the expression of the BACE1 protein, with potential implications in Alzheimer's disease (AD) treatment. Stearic acid (SA) and lactoferrin (Lf) were successfully exploited as brain-targeting ligands to modify cationic polymers (chitosan (CS) or polyethyleneimine (PEI)), and its BBB penetration behavior was evaluated. The intracellular uptake of the dual-targeting drug delivery systems by neuronal cell models, as well as the gene silencing efficiency of recombinant pre-miR-29b, was analyzed in vitro. Labeled pre-miR-29b-CS/PEI-SA-Lf systems showed very strong fluorescence in the cytoplasm and nucleus of RBE4 cells, being verified the delivery of pre-miR-29b to neuronal cells after 1 h transfection. The experiment of transport across the BBB showed that CS-SA-Lf delivered 65% of recombinant pre-miR-29b in a period of 4 h, a significantly higher transport ratio than the 42% found for PEI-SA-Lf in the same time frame. Overall, a novel procedure for the dual targeting of DDS is disclosed, opening new perspectives in nanomedicines delivery, whereby a novel drug delivery system harvests the merits and properties of the different immobilized ligands.
血脑屏障(BBB)的存在在很大程度上阻碍了脑治疗药物的疗效,主要原因是大多数(生物)药物无法穿过血脑屏障。因此,本研究旨在开发用于靶向递送重组前体微小RNA(pre-miR-29b)的纳米载体,预期可降低β-分泌酶1(BACE1)蛋白的表达,这对阿尔茨海默病(AD)的治疗具有潜在意义。硬脂酸(SA)和乳铁蛋白(Lf)已成功用作脑靶向配体来修饰阳离子聚合物(壳聚糖(CS)或聚乙烯亚胺(PEI)),并对其血脑屏障穿透行为进行了评估。在体外分析了双靶向药物递送系统被神经元细胞模型的细胞内摄取情况,以及重组pre-miR-29b的基因沉默效率。标记的pre-miR-29b-CS/PEI-SA-Lf系统在RBE4细胞的细胞质和细胞核中显示出非常强的荧光,在转染1小时后证实pre-miR-29b已递送至神经元细胞。血脑屏障转运实验表明,CS-SA-Lf在4小时内递送了65%的重组pre-miR-29b,这一转运率显著高于同一时间框架内PEI-SA-Lf的42%。总体而言,本研究揭示了一种用于药物递送系统双靶向的新方法,为纳米药物递送开辟了新的前景,即一种新型药物递送系统兼具了不同固定化配体的优点和特性。